This is a randomized, double-blind, placebo controlled, multicenter parallel group comparison study designed to evaluate the efficacy of chronic, passive antibody immunotherapy employing one of two dosed of a mucoid exopolysaccharide Pseudomonas Aeruginosa immune globulin, intravenous (human) (MEP IGIV) in cystic fibrosis (CF) patients with endobronchial colonization by mucoid Pseudomonas aeruginosa.
Showing the most recent 10 out of 724 publications